KRTX – What Karuna Therapeutics Does?

About Karuna Therapeutics

Net Worth$6.83 billion (2022)
HeadquartersBoston, Massachusetts
CEOSteven M. Paul
Revenue$36.96 million (2021)
Net Income-$143.80 million (2021)

What Karuna Therapeutics Does?

Karuna Therapeutics, Inc is a clinical-stage biopharmaceutical business that develops and provides revolutionary medications for those suffering from psychiatric and neurological problems.

KarXT, an oral muscarinic receptor modulator, is the company’s lead product candidate. It is currently undergoing a Phase III clinical trial for the treatment of acute psychosis in schizophrenia patients, as well as for the treatment of central nervous system disorders like negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis.

Additionally, the company concentrates on creating new muscarinic-targeted therapeutic candidates. Eli Lilly and Company, Zai Lab (Shanghai) Co., Ltd., PureTech Health LLC, Charles River Laboratories, and PsychoGenics, Inc. are partners in licence agreements with Karuna Therapeutics, Inc.

The company also has a patent licence arrangement with PureTech Health LLC. In March 2019, the business changed its name from Karuna Pharmaceuticals, Inc. to Karuna Therapeutics, Inc.

KRTX – Karuna Therapeutics Annual Reports PDF

2022 Annual ReportDownload PDF
2021 Annual ReportDownload PDF
2020 Annual ReportDownload PDF


What is the revenue of Karuna Therapeutics?

In 2021, Karuna Therapeutics reported revenue of $36.96 million and net losses of $143.80 million.

Where are the headquarters of Karuna Therapeutics?

Karuna Therapeutics is headquartered in Boston, Massachusetts.